Allogeneic, or off-the-shelf, chimeric antigen receptor (CAR) T-cell therapies will bring new logistical challenges, said Aklilu Tedla, vice president, insights and engagement, regulatory science, cell and gene, Cardinal Health.
Allogeneic, or off-the-shelf, chimeric antigen receptor (CAR) T-cell therapies will bring new logistical challenges, said Aklilu Tedla, vice president, insights and engagement, regulatory science, cell and gene, Cardinal Health.
Transcript
How might the advent of allogeneic CAR T-cell therapies create new logistic problems for storing the treatments and being prepared for potential adverse events?
Logistics, I think you're going to need greater visibility into the supply chain. Right? And you're going to have to think about cold storage and visibility throughout the entire logistical journey. Okay? So, I think that's going to be new, and actually worth thinking about that long and hard about what role we can play there to make sure that the logistical aspects are being met.
This is one of the things that are actually high risk for manufacturers of these therapies, right, is they're innovating to bring them to the market, but then, how can they make sure that as they send them to the patient, that there's visibility into the supply chain, so you can make sure not just about the outcome, but the safety of the products.
You can think of adverse events in terms of at the time of administration, which I think where they're administered today, in hospitals, or in certain settings, you can have the type of monitoring that’s there. What I think is important is how do you monitor continuously? That raises questions about how do you monitor in the home, and in other areas that the patients are, and over what time? So, I think that is something that we're, for example, actively trying to solve.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More